Results 1 to 10 of about 101,972,677 (301)

Bromocriptine in type 2 diabetes mellitus

Indian Journal of Endocrinology and Metabolism, 2011
Bromocriptine mesylate quick-release was approved by the Food and Drug Administration (FDA) in May 2009, for the treatment of type 2 diabetes. Bromocriptine is thought to act on the circadian neuronal activities in the hypothalamus, to reset an ...
C Shivaprasad, Sanjay Kalra
doaj   +1 more source

Six-year Follow-Up of Nonpharmacological and Nonsurgical Obesity Treatments

Diabetes, Metabolic Syndrome and Obesity
Maja J Ekman,1 Martin Ridderstråle1,2 1Department of Clinical Sciences Malmö, Clinical Obesity Research, Lund University, Skåne University Hospital, Malmö, Sweden; 2Department of Translational Type 2 Diabetes Research, Steno Diabetes Center Copenhagen ...
Ekman MJ, Ridderstråle M
doaj  

Type 2 Diabetes and Sarcopenia

Apollo Medicine
Sarcopenia, which is defined as an age-related decline in muscle mass and strength, has been found to have a strong bidirectional relationship with Type 2 diabetes.
Samantha Sathyakumar
doaj   +1 more source

Sleep disorders in type 2 diabetes

Indian Journal of Endocrinology and Metabolism, 2017
Type 2 diabetes mellitus (T2DM) has shown to be associated with higher incidence of sleep disorders, which may be due to disease itself or because of secondary complications or associated comorbidities associated with diabetes. On the other hand, shorter
Deepak Khandelwal, Deep Dutta, Sachin Chittawar, Sanjay Kalra   +3 more
doaj   +1 more source

Deconstructing Type 2 Diabetes [PDF]

Cell, 1999
There is a natural temptation to extrapolate insights from these animal models to explain the pathophysiology of human diabetes. In some cases, the animal model closely resembles the human disease, as is the case with glucokinase knockout mice and MODY2.
openaire   +2 more sources

Individualizing treatment of type 2 diabetes

Sri Lanka Journal of Diabetes Endocrinology and Metabolism, 2014
DOI: http://dx.doi.org/10.4038/sjdem.v4i1.7256 Sri Lanka Journal of Diabetes, Endocrinology and Metabolism 2014; 4: 56 ...
TP Weerarathna
doaj   +1 more source

Type 2 diabetes [PDF]

The Lancet, 2018
Remy, Boussageon, Matthieu, Roustit, Francois, Gueyffier, Benoit V, Tudrej, Michaela B, Rehman   +4 more
openaire   +4 more sources

Type 2 diabetes: the emerging epidemic

South African Family Practice, 2007
This article reports on the prevalence of diabetes in South Africa and gives projections for the epidemic proportions that this disease may take by the year 2030.
Paul Rheeder
doaj   +1 more source

Advances and counterpoints in type 2 diabetes. What is ready for translation into real-world practice, ahead of the guidelines

BMC Medicine
This review seeks to address major gaps and delays between our rapidly evolving body of knowledge on type 2 diabetes and its translation into real-world practice.
Stanley S. Schwartz, Barbara E. Corkey, James R Gavin, Ralph A. DeFronzo, Mary E. Herman   +4 more
doaj   +1 more source

Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study

Journal of Diabetes Research
Conclusion: Empagliflozin initiation was associated with a significantly reduced risk of ACM, HHF, CVM, and ESRD compared with initiation of DPP-4i in patients with T2D when examining routine clinical practice data from Nordic countries.
Gisle Langslet, Thomas Nyström, Dorte Vistisen, Bendix Carstensen, Emilie Toresson Grip, Paula Casajust, Giorgi Tskhvarashvili, Fabian Hoti, Riho Klement, Kristina Karlsdotter, Mikko Tuovinen, Anne Pernille Ofstad, Maria Lajer, Christina Shay, Lisette Koeneman, Soulmaz Fazeli Farsani, Leo Niskanen, Sigrun Halvorsen   +17 more
doaj   +1 more source